Jennifer R. Brown, MD, PhD, on ALPINE Data, CLL Highlights at ASH 2022

By Jennifer R. Brown, MD, PhD - Last Updated: February 8, 2024

Blood Cancers Today caught up with the Society of Hematologic Oncology President Jennifer R. Brown, MD, PhD, to find out what she was watching at the 64th American Society of Hematology Annual Meeting. Dr. Brown highlighted data from the phase III ALPINE study, which compared zanubrutinib with ibrutinib as a treatment for patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Post Tags:ASH22

Expert Panel Discusses Clinical Data, Practice of BTK Inhibitor, B-Cell Lymphoma 2 Inhibitor Use in CLL

Andrew MorenoChronic Lymphocytic Leukemia | March 7, 2025

The several considerations involved with these agent classes make discussions with patients of treatment decisions crucial.

Stepping Forward in CLL: Novel Agents and BTKi/BCL2i Combination Strategies

Melissa BadamoChronic Lymphocytic Leukemia | March 6, 2025

BTKi/BCL2i combinations may change how CLL treatment is offered over a patient’s lifespan, said Kerry Rogers, MD.

CD5-Targeting CAR T-Cell Therapy Receives FDA Orphan Drug Designation for T-Cell Lymphoma Use

Andrew MorenoT-Cell Lymphoma | January 30, 2025

Therapy also in development for T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma.

FDA Approves In-Vitro Assay to Identify B-Cell Lymphomas, Plasma Cell Neoplasms

Andrew MorenoAggressive B-Cell Lymphoma | January 29, 2025

The single-slide test helps clinicians differentiate more than 60 subtypes of these diseases from normal immune response.

Comparing Risk Scores for Disease Progression in Untreated CLL

Melissa BadamoChronic Lymphocytic Leukemia | January 29, 2025

The IPS-E, CR0, AIPS-E, CLL-IPI, and Barcelona-Brno risk scores can predict time to first treatment in CLL patients.

Jennifer R. Brown, MD, PhD, on ALPINE Data, CLL Highlights at ASH 2022

Related Posts